TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23032742

Group type: EXPERIMENTAL
Intervention: Vaccination with modified HLA class I tumor peptides (Melan‐A/MART‐1([27L]), gp100([210M]), NY‐ESO‐1([165V]), and Survivin([97M])) emulsified in Montanide ISA51, injected subcutaneously with cyclophosphamide (300 mg/m(2)) and low‐dose IL‐2 (3 × 10(6) IU).
Number of subjects: 43

Group type: COMPARATOR
Intervention: Observation (control group).
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Vaccination with modified HLA class I tumor peptides.
Number of subjects: 43
Study: 19541691

Group type: EXPERIMENTAL
Intervention: Collagen-gentamicin sponges applied between sternal halves in addition to routine intravenous antibiotics
Number of subjects: 1359

Group type: COMPARATOR
Intervention: Control group (previous study with intravenous prophylaxis only)
Number of subjects: 1359
Study: 17641452

Group type: EXPERIMENTAL
Intervention: Extra-curricular aerobic dynamic physical activity (swimming, water games, folk dance, soccer) for 35 weeks, 45 min of physical classes plus three 60 min sessions weekly
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (43 overweight or obese boys) with only two curricular physical education classes weekly
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (75 non-overweight and non-obese boys)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Extra-curricular aerobic dynamic physical activity
Number of subjects: 31
Study: 15365965

Group type: EXPERIMENTAL
Intervention: Low-dose intraperitoneal immunoglobulin (IgG) 2 mL (320 mg) with every exchange
Number of subjects: 24

Group type: COMPARATOR
Intervention: Empiric antibiotic treatment (2-week IP ampicillin+sulbactam/netilmycin combination)
Number of subjects: 24
Study: 12226037

Group type: EXPERIMENTAL
Intervention: Distractive auditory stimuli (DAS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no DAS)
Number of subjects: 24
Study: 11231701

Group type: EXPERIMENTAL
Intervention: Folic acid 0.2 mg/d
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Folic acid 0.4 mg/d
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Folic acid 0.6 mg/d
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Folic acid 0.8 mg/d
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Folic acid 1.0 mg/d
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 9381718

Group type: EXPERIMENTAL
Intervention: Neutrophils in patients with internal endometriosis
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (20 healthy women)
Number of subjects: 16
Study: 8349067

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg/d)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Omeprazole (20 mg/d)
Number of subjects: 144
Study: 3768492

Group type: EXPERIMENTAL
Intervention: Intravenous administration of trimazosin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral administration of trimazosin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1-hydroxytrimazosin (metabolite)
Number of subjects: 6
Study: 28988765

Group type: EXPERIMENTAL
Intervention: UroRCC multi-peptide vaccine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control cohort (metastasectomy only)
Number of subjects: 19
Study: 30355323

Group type: EXPERIMENTAL
Intervention: Autologous adipose tissue injection
Number of subjects: 54

Group type: COMPARATOR
Intervention: Hyaluronic acid injection
Number of subjects: 54
Study: 27082493

Group type: EXPERIMENTAL
Intervention: System-paced secondary task under time pressure
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Self-regulation group (self-paced secondary task)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Baseline driving performance without distraction
Number of subjects: 39
Study: 24625239

Group type: COMPARATOR
Intervention: Olive oil (n=30)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Canola oil (n=33)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control oil (n=30)
Number of subjects: 93
Study: 23020132

Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg) plus trametinib (2 mg)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Dabrafenib monotherapy
Number of subjects: 247
Study: 19996977

Group type: EXPERIMENTAL
Intervention: 10-day oral quadruple therapy regimen with omeprazole (20 mg, twice daily), tetracycline (750 mg, three times daily), metronidazole (500 mg, three times daily), and bismuth potassium citrate (300 mg, twice daily)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo regimen
Number of subjects: 277
Study: 18751503

Group type: EXPERIMENTAL
Intervention: Clindamycin 75 mg capsule (test 1)
Number of subjects: 24
Study: 15701488

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN) starting on postoperative day 3
Number of subjects: 42

Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN) starting on postoperative day 3
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 42
Study: 12791430

Group type: EXPERIMENTAL
Intervention: CO2 laser-induced noxious stimuli (80% frequent) with rare stronger-intensity deviant stimuli (10% target, 10% distractor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strong stimuli delivered alone on one hand without instruction (100%, no-task stimuli)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distractor stimuli (10%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target stimuli (10%)
Number of subjects: 0
Study: 10619544

Group type: EXPERIMENTAL
Intervention: Focusing on electric shocks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distraction from electric shocks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Repeated administration of electric shocks
Number of subjects: 60
Study: 7503006

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 46
Study: 1820293

Group type: EXPERIMENTAL
Intervention: 25 mg captopril t.i.d.
Number of subjects: 90

Group type: COMPARATOR
Intervention: 40 mg frusemide or placebo
Number of subjects: 90
Study: 31755915

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (up to 2 doses before surgery and every 3 weeks afterward until disease progression or unacceptable toxicities)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 15
Study: 31268624

Group type: COMPARATOR
Intervention: Certolizumab pegol
Number of subjects: 776

Group type: COMPARATOR
Intervention: Abatacept
Number of subjects: 776

Group type: COMPARATOR
Intervention: CT-P13 (biosimilar infliximab)
Number of subjects: 776
Study: 28034710

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 7600

Group type: EXPERIMENTAL
Intervention: Surface ablation
Number of subjects: 7600

Group type: EXPERIMENTAL
Intervention: ReLEx
Number of subjects: 7600

Group type: EXPERIMENTAL
Intervention: Posterior chamber phakic IOL
Number of subjects: 7600

Group type: EXPERIMENTAL
Intervention: Iris-supported phakic IOL
Number of subjects: 7600
Study: 25788320

Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo-oophorectomy (RRSO)
Number of subjects: 934
Study: 25618968

Group type: EXPERIMENTAL
Intervention: Anshendingzhi decoction (ASDZD)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Danzhixiaoyao pill (DZXYP)
Number of subjects: 78
Study: 22738907

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control/delayed‐treatment condition
Number of subjects: 0
Study: 18395716

Group type: EXPERIMENTAL
Intervention: Coenzyme Q(10), 200 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17576043

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 5
Study: 15293818

Group type: EXPERIMENTAL
Intervention: TTO-gel (2.5 per cent)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) gel (0.2 per cent)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 49
Study: 11165126

Group type: EXPERIMENTAL
Intervention: Mistletoe extract treatment (ML-1 standardized mistletoe preparation)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Control group (no mistletoe treatment)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Mistletoe extract treatment
Number of subjects: 477
Study: 9710397

Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 25 microg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transnasal placebo
Number of subjects: 60
Study: 7975966

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (3 mg vaginal tablet or 0.5 mg intracervical gel)
Number of subjects: 542
Study: 2686737

Group type: EXPERIMENTAL
Intervention: Captopril (twice or three times daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 21
Study: 782240

Group type: EXPERIMENTAL
Intervention: Potassium acid phosphate
Number of subjects: 71

Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 71

Group type: COMPARATOR
Intervention: Low calcium diet only
Number of subjects: 71
Study: 30576475

Group type: EXPERIMENTAL
Intervention: Perturbation‐based balance training (PBT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Conventional intensive balance training (CIBT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: PBT and CIBT
Number of subjects: 24
Study: 28753702

Group type: EXPERIMENTAL
Intervention: FICE-guided pCLE with targeted biopsies (group A)
Number of subjects: 238

Group type: COMPARATOR
Intervention: FICE with standard biopsies (group B)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: FICE-guided pCLE with targeted biopsies
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: pCLE-guided targeted biopsies
Number of subjects: 238
Study: 25850528

Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control Therapy (CT)
Number of subjects: 15
Study: 23600363

Group type: EXPERIMENTAL
Intervention: Alogliptin in addition to αGI (Intake 1, 2, and 3 groups)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alogliptin in addition to αGI (Intake 3 group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alogliptin alone (Intake 0 group)
Number of subjects: 0
Study: 21789887

Group type: EXPERIMENTAL
Intervention: BCAA Drink
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19404617

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg acute and 300 mg sub-acute)
Number of subjects: 0
Study: 16940077

Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin-tazobactam 12 g/1.5 g administered continuously over 24 h
Number of subjects: 262

Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin-tazobactam 3 g/0.375 g administered over 30 min every 6 h for 4 to 14 days
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin-tazobactam
Number of subjects: 262

Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin-tazobactam
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Continuous infusion and intermittent infusion
Number of subjects: 262
Study: 14676594

Group type: COMPARATOR
Intervention: Low-calorie diet with oral placebo for 5 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-calorie diet with oral vitamin E (400 mg/d x 2 months, 100 mg/d x 3 months)
Number of subjects: 28
Study: 11196236

Group type: EXPERIMENTAL
Intervention: Formula with LCPUFA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formula without LCPUFA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formula with LCPUFA (preterm infants)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formula without LCPUFA (full-term infants)
Number of subjects: 0
Study: 9310515

Group type: EXPERIMENTAL
Intervention: Head Elevated Tilt Position (HETP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Horizontal Position
Number of subjects: 12
Study: 8379674

Group type: EXPERIMENTAL
Intervention: FAM (5‐FU, ADM, MMC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: FEM (5‐FU, EPIR, MMC)
Number of subjects: 21
Study: 3706498

Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 73

Group type: COMPARATOR
Intervention: Parent training
Number of subjects: 73
Study: 31356703

Group type: EXPERIMENTAL
Intervention: massed PE (10 sessions delivered over 2 weeks)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: spaced PE (10 sessions delivered over 8 weeks)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: present‐centered therapy (PCT; 10 sessions delivered over 8 weeks)
Number of subjects: 331

Group type: COMPARATOR
Intervention: minimal contact control (MCC; weekly therapist phone check‐in for 4 weeks)
Number of subjects: 331

Group type: COMPARATOR
Intervention: spaced PE vs. PCT
Number of subjects: 331
Study: 28567669

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MCT) group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) group
Number of subjects: 67
Study: 25633475

Group type: EXPERIMENTAL
Intervention: Tai Chi (12 or 24 weeks, once or twice per week)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Aerobic exercise (supervised, twice per week for 24 weeks)
Number of subjects: 216
Study: 22647826

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg, lansoprazole 30 mg twice daily for 5 days)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Triple therapy (amoxicillin 1000 mg, clarithromycin 500 mg, lansoprazole 30 mg twice daily for 7 days)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Concomitant therapy
Number of subjects: 270

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 270
Study: 21875880

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 19356761

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) training program for 16 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group received general education for 16 weeks
Number of subjects: 40
Study: 17357293

Group type: EXPERIMENTAL
Intervention: Multiple Daily Insulin Injections (MDI)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Continuous Intravenous Insulin Infusion (IVII)
Number of subjects: 90
Study: 15243929

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (ACP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no ACP vaccine)
Number of subjects: 200
Study: 11181931

Group type: EXPERIMENTAL
Intervention: Cocaine 0.2 mg/kg i.v.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cocaine 0.4 mg/kg i.v.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cocaine (both doses)
Number of subjects: 34
Study: 9389848

Group type: EXPERIMENTAL
Intervention: NVHD-2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NVHD-6
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no NVHD)
Number of subjects: 30
Study: 8198906

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: droperidol 1.25 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: saline 0.9%
Number of subjects: 120
Study: 2897558

Group type: EXPERIMENTAL
Intervention: Acetylcholine sweatspot test (0.1 ml 1% acetylcholine administered intradermally)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pupil test
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cardiovascular autonomic function tests
Number of subjects: 24
Study: 30185575

Group type: EXPERIMENTAL
Intervention: Unguided Internet-based cognitive behaviour therapy (ICBT)
Number of subjects: 120
Study: 26522083

Group type: EXPERIMENTAL
Intervention: Azacitidine/chemotherapy (arm-A)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Chemotherapy (arm-B)
Number of subjects: 214
Study: 25148170

Group type: EXPERIMENTAL
Intervention: Hepatic steatosis patients (n = 71)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Patients without hepatic steatosis
Number of subjects: 304
Study: 22213783

Group type: EXPERIMENTAL
Intervention: Consent type with varying levels of control over data release decisions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up interview
Number of subjects: 0
Study: 20923081

Group type: EXPERIMENTAL
Intervention: Exposure to perfumes
Number of subjects: 0

Group type: COMPARATOR
Intervention: No odors (control)
Number of subjects: 0
Study: 18661059

Group type: COMPARATOR
Intervention: Routine surgical modality (Group 1)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Preserving the fascia parotideomasseterica and great auricular nerve with partial parotidectomy (Group 2)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Group 1 (Routine surgical modality)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Group 2 (Modified technique)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 16186270

Group type: EXPERIMENTAL
Intervention: HIIP 2.6 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HIIP 5.2 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HIIP 7.8 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HIIP
Number of subjects: 20

Group type: COMPARATOR
Intervention: SC lispro
Number of subjects: 20
Study: 11489700

Group type: EXPERIMENTAL
Intervention: Doxazosin 2 mg
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Doxazosin 8 mg
Number of subjects: 272
Study: 9566806

Group type: EXPERIMENTAL
Intervention: Daily dosing of buprenorphine (maintenance doses every 24 h)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Alternate-day dosing of buprenorphine (double maintenance doses every 48 h with placebo on intervening days)
Number of subjects: 17
Study: 8070504

Group type: EXPERIMENTAL
Intervention: Conventional formulation of metoprolol (100 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sustained‐release formulation of metoprolol (100 mg)
Number of subjects: 7
Study: 3135786

Group type: EXPERIMENTAL
Intervention: Praziquantel (2 x 20 mg kg‐1)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Oltipraz (2 x 15 mg kg‐1)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Mass chemotherapy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Follow-up after treatment
Number of subjects: 111
Study: 30911857

Group type: EXPERIMENTAL
Intervention: Absorb BVS oversized group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Absorb BVS non-oversized group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Xience EES oversized group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Xience EES non-oversized group
Number of subjects: 80
Study: 28583342

Group type: EXPERIMENTAL
Intervention: Flibanserin (100 mg/d)
Number of subjects: 745

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study: 23299714

Group type: EXPERIMENTAL
Intervention: Kamut products (bread, pasta, and crackers)
Number of subjects: 22
Study: 21295494

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day for 30 days, then 10 mg/day for 60 days
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day to 10 mg/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 33
Study: 20606776

Group type: EXPERIMENTAL
Intervention: HESA-A (25 mg/Kg twice a day orally for 4 weeks)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo (same method as treatment for 4 weeks)
Number of subjects: 280
Study: 16696414

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen suspension (3 doses given 24 hours apart)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 42
Study: 15208824

Group type: EXPERIMENTAL
Intervention: Aprepitant (Emend) in combination with standard antiemetic agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antiemetic therapy
Number of subjects: 0
Study: 11134441

Group type: EXPERIMENTAL
Intervention: Abnormal heart rate characteristics (HRC)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Score for Neonatal Acute Physiology (SNAP)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Third moment (skewness) of heart rate characteristics
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Neonatal Therapeutic Intervention Scoring System (NTISS)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Heart rate characteristics (HRC) and clinical scores
Number of subjects: 89
Study: 9781529

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 8143470

Group type: EXPERIMENTAL
Intervention: 37.5 g/day of albumin until the circulating albumin concentration increased to > 3.0 g/dL (> 30 g/L)
Number of subjects: 219

Group type: COMPARATOR
Intervention: No supplemental albumin
Number of subjects: 219
Study: 2646246

Group type: EXPERIMENTAL
Intervention: Topically applied 2% glycopyrrolate lotion/cream
Number of subjects: 61

Group type: COMPARATOR
Intervention: Topically applied placebo
Number of subjects: 61
Study: 31500854

Group type: EXPERIMENTAL
Intervention: Sevelamer 0.8 g (low-dose)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sevelamer 2.4 g (high-dose)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sevelamer (high-dose) in highest baseline phosphate quartile group
Number of subjects: 72
Study: 28476766

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study: 25701101

Group type: EXPERIMENTAL
Intervention: Home‐based Post‐Hip Fracture Rehabilitation program (6 months)
Number of subjects: 232
Study: 23539427

Group type: EXPERIMENTAL
Intervention: Test formulation of bisoprolol fumarate 5 mg and hydrochlorothiazide 6.25 mg
Number of subjects: 18
Study: 21270370

Group type: EXPERIMENTAL
Intervention: Staggered meal consumption (2 hours with 3 within-meal pauses)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nonstaggered meal consumption (0.5 hours)
Number of subjects: 38